7th Annual USC Multi-Disciplinary Breast Cancer Symposium
Combined Inhibition of Endocrine Therapy and the PI3K/AKT/mTOR Pathways Appears Superior to Either Component in HR+ Metastatic Breast Cancer
Login to view comments.
Click here to Login
Videos